Despite recent advances in understanding the neurobiology of addiction, there is a persistent gap in the application of knowledge gained from basic science studies to clinical practice in the field of addiction. A new generation of behavioral, psychopharmacology, neuroimaging, molecular genetic and molecular neuroscience studies has broad clinical implications and these studies bring the potential to bridge the gap between basic and clinical research. Despite the quality of the available science, actual progress in bridging this gap depends also upon the availability of appropriately trained young scientists. This purpose of the RTFSA-P is to meet this need by providing post-doctoral training for a total of 4 physicians or PhDs interested in careers in translational or intervention research in the field of substance abuse. The proposed RTFSA-P is a two-year program in the Division of Substance Abuse (DSA), Department of Psychiatry, Yale University School of Medicine, and will afford post-doctoral trainees the opportunity to devote virtually full-time effort during the initial phase of their careers to developing the skills and experience needed to become independent researchers in the field of clinical or translational research in substance use disorders. The DSA is an ongoing, stable substance abuse research program that began in 1968 and now encompasses over 78 major funded projects including 7 Centers covering a broad scope of topics and research methodologies. This facilitates research that moves rapidly and in both directions from preclinical projects (""""""""bench"""""""") to clinical studies (""""""""bedside"""""""" and """"""""community""""""""). Applicants will be MD's or PhD post-doctoral candidates trained in specialties that include psychiatry, internal medicine, clinical psychology or neuroscience. Candidates will be selected by an admission committee based on their potential for excellence in the field of translational or intervention research in substance abuse. The RTFSA-P program includes (1) individualized research preceptorship, (2) successful completion of a translational-research project, (3) a core curriculum, which include seminars on substance abuse clinical research and treatment, biostatistics and research design, the responsible conduct of scientific research and grant writing skills and (4) individualized participation in seminars of interest in the Department, Medical School and University. The training facilities include the major institutions affiliated with Yale School of Medicine, Department of Psychiatry. At the conclusion of training, applicants will be well suited for independent careers in translational or intervention research in the field of addiction.

Public Health Relevance

Clinical and translational research is vital to the development of new treatments for substance use disorders and for understanding the underlying causes of these disorders. The proposed RTFSA-P is a two-year training program in the Division of Substance Abuse (DSA), Department of Psychiatry, Yale University School of Medicine, dedicated to training young physicians and PhD-level trainees in research in the field of clinical and translational substance abuse research. The program trains 4 fellows per year and at the end of training, fellows should be well suited for independent careers in substance abuse research.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Aklin, Will
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Schools of Medicine
New Haven
United States
Zip Code
Verplaetse, Terril L; Weinberger, Andrea H; Ashare, Rebecca L et al. (2018) Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. J Psychopharmacol 32:1003-1009
Roberts, Walter; Ralevski, Elizabeth; Verplaetse, Terril L et al. (2018) Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. J Subst Abuse Treat 94:91-96
Roberts, Walter; Moore, Kelly E; Peltier, MacKenzie R et al. (2018) Electronic Cigarette Use and Risk of Harmful Alcohol Consumption in the U.S. Population. Alcohol Clin Exp Res 42:2385-2393
Roberts, Walter; McKee, Sherry A (2018) Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes. Exp Clin Psychopharmacol 26:49-57
Peltier, MacKenzie R; Roys, Melanie R; Waters, Aaron F et al. (2018) Motivation and readiness for tobacco cessation among nicotine dependent postmenopausal females: A pilot study. Exp Clin Psychopharmacol 26:125-131
Morie, Kristen P; Wu, Jia; Landi, Nicole et al. (2018) Feedback processing in adolescents with prenatal cocaine exposure: an electrophysiological investigation. Dev Neuropsychol 43:183-197
Yip, Sarah W; Worhunsky, Patrick D; Xu, Jiansong et al. (2018) Gray-matter relationships to diagnostic and transdiagnostic features of drug and behavioral addictions. Addict Biol 23:394-402
Yip, Sarah W; Potenza, Marc N (2018) Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment. Clin Psychol Rev 64:41-56
Verplaetse, Terril L; Moore, Kelly E; Pittman, Brian P et al. (2018) Intersection of stress and gender in association with transitions in past year DSM-5 substance use disorder diagnoses in the United States. Chronic Stress (Thousand Oaks) 2:
Roberts, Walter; Shi, Julia M; Tetrault, Jeanette M et al. (2018) Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study. J Addict Med 12:227-233

Showing the most recent 10 out of 130 publications